Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe + simvastatin (Merck/Schering-Plough).

Nicholas A Flores1

  • 1naflor40@hotmail.com

Current Opinion in Investigational Drugs (London, England : 2000)
|October 27, 2004
PubMed
Summary

Ezetimibe and simvastatin, a new combination drug, has been launched for treating high cholesterol. This fixed-dose tablet combines a cholesterol absorption inhibitor with an HMG CoA reductase inhibitor.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrophysiological effects accompanying regression of left ventricular hypertrophy.

Cardiovascular research·2003
Same author

Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo.

Current opinion in investigational drugs (London, England : 2000)·2002
See all related articles

Area of Science:

  • Cardiovascular Pharmacology
  • Medicinal Chemistry
  • Pharmaceutical Development

Background:

  • Hypercholesterolemia is a significant risk factor for cardiovascular disease.
  • Current treatments involve statins and cholesterol absorption inhibitors, often requiring multiple pills.
  • A fixed-dose combination offers potential for improved patient adherence and efficacy.

Purpose of the Study:

  • To introduce the development and launch of ezetimibe + simvastatin (Vytorin).
  • To highlight the therapeutic potential of this fixed-dose combination for hypercholesterolemia management.

Main Methods:

  • Development of a fixed-dose combination tablet containing ezetimibe and simvastatin.
  • Regulatory approval processes in key markets.

Main Results:

  • Ezetimibe + simvastatin (Vytorin) has been developed and launched.
  • The drug combines ezetimibe (cholesterol absorption inhibitor) and simvastatin (HMG CoA reductase inhibitor).
  • Launched in Germany and Mexico by April 2004, approved in the US in July 2004.

Conclusions:

  • Vytorin represents a novel therapeutic option for hypercholesterolemia.
  • The fixed-dose combination aims to simplify treatment regimens for patients.

Related Experiment Videos